Literature DB >> 23169500

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

Akihiro Tamiya1, Isamu Okamoto, Masaki Miyazaki, Shigeki Shimizu, Masanori Kitaichi, Kazuhiko Nakagawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23169500     DOI： 10.1200/JCO.2012.43.3730

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.

Authors:  Evelyn M Brosnan; Andrew J Weickhardt; Xian Lu; Delee A Maxon; Anna E Barón; Michel Chonchol; D Ross Camidge
Journal:  Cancer       Date:  2013-11-20       Impact factor: 6.860

2.  Managing treatment-related adverse events associated with Alk inhibitors.

Authors:  J M Rothenstein; N Letarte
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 3.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

4.  Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

Authors:  Yuzo Yamamoto; Isamu Okamoto; Kohei Otsubo; Eiji Iwama; Naoki Hamada; Taishi Harada; Koichi Takayama; Yoichi Nakanishi
Journal:  Invest New Drugs       Date:  2015-09-04       Impact factor: 3.850

Review 5.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

6.  Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient.

Authors:  Shaoyu Yang; Liming Wu; Xin Li; Jie Huang; Jianbo Zhong; Xueqin Chen
Journal:  Mol Clin Oncol       Date:  2018-01-11

7.  Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Authors:  Shigenari Nukaga; Katsuhiko Naoki; Tetsuro Kamo; Keita Masuzawa; Hiroyuki Yasuda; Kenzo Soejima; Tomoko Betsuyaku
Journal:  Mol Clin Oncol       Date:  2016-03-30

8.  Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy.

Authors:  Vinayak V Maka; Uma Maheshwari Krishnaswamy; N Anil Kumar; Rohith Chitrapur; Nalini Kilara
Journal:  Oxf Med Case Reports       Date:  2014-04-08

9.  Successful crizotinib rechallenge after crizotinib-induced organizing pneumonia in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Nobuhiro Asai; Toyoharu Yokoi; Etsuro Yamaguchi; Akihito Kubo
Journal:  Case Rep Oncol       Date:  2014-09-27

Review 10.  Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.

Authors:  Eiji Iwama; Isamu Okamoto; Taishi Harada; Koichi Takayama; Yoichi Nakanishi
Journal:  Onco Targets Ther       Date:  2014-03-05       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.